ホーム>>Signaling Pathways>> Others>>LDN-27219

LDN-27219

カタログ番号GC13015

LDN-27219 は、TGase の可逆的でゆっくり結合する阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

LDN-27219 化学構造

Cas No.: 312946-37-5

サイズ 価格 在庫数
10mg
$117.00
Please Inquire
50mg
$496.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LDN-27219 is a reversible and slow-binding inhibitor of tissue transglutaminase (TGases) with IC50 value of 250nM for TGase 2 [1, 2].

LDN-27219 is discovered as a moderately potent inhibitor of TGase. It shows inhibitory activity against hTGase with IC50 value of 0.6μM. LDN-27219 is also a selective inhibitor. It has no effect on Factor XIIIa or caspase 3 at concentration up to 50μM. Besides that, LDN-27219 is found to be mutually exclusive inhibitors with GTP which is an allosteric inhibitor of TGase. It binds at sites other than the GTP site or the active site of the enzyme. The mechanism of LDN-27219 is also not similar with GTP. It has a modest effect on the binding of calcium. Moreover, it is found that LDN-27219 is a competitive inhibitor of the hTGase-catalyzed hydrolysis of Z-Pro-Gln-Ala-Trp [1].

References:
[1] Case A, Stein R L. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry, 2007, 46(4): 1106-1115.
[2] Duval E, Case A, Stein R L, et al. Structure–activity relationship study of novel tissue transglutaminase inhibitors. Bioorganic & medicinal chemistry letters, 2005, 15(7): 1885-1889.

レビュー

Review for LDN-27219

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LDN-27219

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.